Compare Crispr Therapeutics AG (CRSP) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs SOLAI Limited — how do they compare? Crispr Therapeutics AG trades at $53.98 (market cap $5.23B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Crispr Therapeutics AG is far larger — about 313.4× SOLAI Limited's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.
| CRSP | SLAI | |
|---|---|---|
Market Cap | $5.23B | $16.69M |
Sector | Health | Technology |
52-Week High | $76.78 | $26.74 |
52-Week Low | $44.34 | $2.74 |
Enterprise Value | $3.65B | $16.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
SLAI trades at $3.72 with no recent price movement, showing mixed technical signals despite a bullish overall rating. The company faces severe financial distress with negative profit margins (-134.63% net income margin) and declining revenue, compounded by NYSE delisting proceedings initiated in July 2026. Recent corporate actions include a 7:1 reverse stock split completed in July 2026 and the acquisition of a 51% stake in NEURALAND, signaling strategic shifts amid operational challenges.
The outlook remains highly speculative with significant execution and liquidity risks. While technical indicators suggest potential short-term momentum, fundamental weaknesses and delisting uncertainty create substantial downside risk. Investors should approach with caution given the company's negative profitability and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
